NYSE:TEVATeva Pharmaceutical Industries Stock Price, Forecast & News

Teva Pharmaceutical Industries' stock was trading at $9.01 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TEVA shares have increased by 31.7% and is now trading at $11.87.
View which stocks have been most impacted by Coronavirus.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 3 sell ratings, 10 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) announced its earnings results on Wednesday, August, 5th. The company reported $0.55 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.53 by $0.02. The firm earned $3.87 billion during the quarter, compared to the consensus estimate of $3.94 billion. Teva Pharmaceutical Industries had a return on equity of 17.88% and a net margin of 0.03%. The business's revenue for the quarter was down 7.3% on a year-over-year basis. During the same quarter last year, the company earned $0.60 EPS.
View Teva Pharmaceutical Industries' earnings history.

Teva Pharmaceutical Industries updated its FY20 earnings guidance on Wednesday, August, 5th. The company provided EPS guidance of $2.30 to $2.55 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.49. The company issued revenue guidance of $16.6 billion to $17 billion, compared to the consensus revenue estimate of $16.83 billion.

18 brokerages have issued 12 month target prices for Teva Pharmaceutical Industries' stock. Their forecasts range from $8.00 to $16.00. On average, they expect Teva Pharmaceutical Industries' share price to reach $12.36 in the next twelve months. This suggests a possible upside of 4.1% from the stock's current price.
View analysts' price targets for Teva Pharmaceutical Industries.

News coverage about TEVA stock has been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Teva Pharmaceutical Industries earned a news sentiment score of -1.9 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
View the latest news about Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries saw a decrease in short interest during the month of December. As of December 31st, there was short interest totaling 57,460,000 shares, a decrease of 14.7% from the December 15th total of 67,380,000 shares. Based on an average trading volume of 19,350,000 shares, the short-interest ratio is presently 3.0 days.
View Teva Pharmaceutical Industries' Short Interest.

Some companies that are related to Teva Pharmaceutical Industries include ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Royalty Pharma (RPRX), UCB (UCBJF), Genmab A/S (GMAB), Genmab A/S (GNMSF), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Shiseido (SSDOY), Beigene (BGNE), Merck KGaA (MKGAF), Alnylam Pharmaceuticals (ALNY), Horizon Therapeutics (HZNP), Catalent (CTLT) and Sarepta Therapeutics (SRPT).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), NVIDIA (NVDA), AT&T (T), Alibaba Group (BABA), Bank of America (BAC), Gilead Sciences (GILD), Micron Technology (MU), Intel (INTC), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Teva Pharmaceutical Industries' stock is owned by a variety of institutional and retail investors. Top institutional investors include Menora Mivtachim Holdings LTD. (1.64%), Phoenix Holdings Ltd. (1.07%), Harel Insurance Investments & Financial Services Ltd. (0.70%), Swiss National Bank (0.40%), Sumitomo Mitsui Trust Holdings Inc. (0.38%) and Beck Mack & Oliver LLC (0.37%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell, Sol J Barer and Sven Dethlefs.
View institutional ownership trends for Teva Pharmaceutical Industries.

TEVA stock was sold by a variety of institutional investors in the last quarter, including Psagot Investment House Ltd., Personal Resources Investment & Strategic Management Inc., Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management, Cambridge Investment Research Advisors Inc., Strs Ohio, Raymond James & Associates, Dfpg Investments LLC, and Sumitomo Mitsui Trust Holdings Inc.. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, and Richard Daniell.
View insider buying and selling activity for Teva Pharmaceutical Industries.

TEVA stock was acquired by a variety of institutional investors in the last quarter, including Menora Mivtachim Holdings LTD., Harel Insurance Investments & Financial Services Ltd., Phoenix Holdings Ltd., SG Americas Securities LLC, Centric Wealth Management, Janney Montgomery Scott LLC, Meitav Dash Investments Ltd., and Swiss National Bank.
View insider buying and selling activity for Teva Pharmaceutical Industries.

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TEVA stock can currently be purchased for approximately $11.87.

Teva Pharmaceutical Industries has a market capitalization of $12.96 billion and generates $16.89 billion in revenue each year. The company earns $-998,000,000.00 in net income (profit) each year or $2.31 on an earnings per share basis. Teva Pharmaceutical Industries employs 40,039 workers across the globe.

The official website for Teva Pharmaceutical Industries is www.tevapharm.com.

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3914-8171 or via email at [email protected]